Vyome Holdings, Inc. (NASDAQ:HIND) Short Interest Up 23.3% in March
by Doug Wharley · The Cerbat GemVyome Holdings, Inc. (NASDAQ:HIND – Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 158,474 shares, an increase of 23.3% from the March 15th total of 128,513 shares. Based on an average trading volume of 32,309 shares, the short-interest ratio is presently 4.9 days. Approximately 3.4% of the shares of the company are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e-)” rating on shares of Vyome in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Vyome presently has an average rating of “Hold” and a consensus target price of $15.00.
Check Out Our Latest Report on Vyome
Vyome Trading Down 0.9%
HIND traded down $0.02 on Thursday, reaching $2.22. The company had a trading volume of 28,219 shares, compared to its average volume of 740,823. The company has a fifty day moving average of $2.52 and a 200-day moving average of $3.77. The company has a market capitalization of $15.58 million, a P/E ratio of -0.02 and a beta of 1.41. Vyome has a one year low of $1.75 and a one year high of $56.38.
Hedge Funds Weigh In On Vyome
A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC acquired a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned approximately 0.80% of Vyome at the end of the most recent quarter. 22.06% of the stock is owned by hedge funds and other institutional investors.
Vyome Company Profile
ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.